--- title: "Gyre Therapeutics (GYRE) news: offering and convertible notes" url: "https://aibio.space/companies/gyre-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "GYRE offering, convertible notes and merger news: Gyre Therapeutics sets up $50,000,000 at-the-market stock program with Jefferies. Gyre Therapeutics, Inc." --- GYRE Gyre Therapeutics, Inc. NASDAQ · United States # Gyre Therapeutics (GYRE) news GYRE offering, convertible notes and merger news Mergers · 2026-05-04 ## [Gyre Therapeutics completes all-stock acquisition of Cullgen valued at about $300 million](https://aibio.space/news/gyre-therapeutics-completes-all-stock-acquisition-cullgen-valued-about/) Gyre closed its merger with Cullgen on May 4, 2026. Cullgen holders get Gyre common and Series B preferred stock, and Cullgen's former CEO Ying Luo becomes Gyre's CEO. ## Latest Gyre Therapeutics news 1. 2026-03-02 Financings [Gyre Therapeutics agrees to acquire Cullgen in all-stock deal valued at about $300 million](https://aibio.space/news/gyre-therapeutics-agrees-acquire-cullgen-all-stock-deal-valued-about/) Gyre Therapeutics agreed to buy privately held Cullgen in an all-stock deal valued at about $300 million, issuing common stock and Series B convertible preferred. Until stockholders approve the conversion, Gyre may not issue more than 19.99% of its stock, and Cullgen's lead drug has completed only a Phase 1 trial. 2. 2024-11-27 Financings [Gyre Therapeutics sets up $50,000,000 at-the-market stock program with Jefferies](https://aibio.space/news/gyre-therapeutics-sets-up-50-000-000-market-stock-program-jefferies/) Jefferies LLC is the sales agent for up to $50,000,000 of common stock. Its commission is up to 3.0% of gross proceeds, and a significant part of the business runs through a Chinese subsidiary. ## Gyre Therapeutics at a glance - **Ticker**: GYRE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $57.3 million ### Related companies - [GT Biopharma](https://aibio.space/companies/gt-biopharma/) NASDAQ: GTBP - [Allarity Therapeutics](https://aibio.space/companies/allarity-therapeutics/) NASDAQ: ALLR - [Avalo Therapeutics](https://aibio.space/companies/avalo-therapeutics/) NASDAQ: AVTX - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET - [Werewolf Therapeutics](https://aibio.space/companies/werewolf-therapeutics/) NASDAQ: HOWL - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) NASDAQ: TELO - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) NASDAQ: ASMB - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) NASDAQ: TARA ### Also on NASDAQ - [Palatin Technologies](https://aibio.space/companies/palatin-technologies/) PTN - [FEMASYS INC](https://aibio.space/companies/femasys/) FEMY - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics/) IRLA - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) BDTX - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) CARL - [Aura Biosciences](https://aibio.space/companies/aura-biosciences/) AURA ## What Gyre Therapeutics does Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases. It operates in the PRC through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.), and has U.S. operations headquartered in San Diego, California. Its commercial portfolio in the PRC is built on ETUARY (pirfenidone) for idiopathic pulmonary fibrosis, which generated annual sales of $106.1 million in 2025. The portfolio also includes Etorel (nintedanib), approved as a standard-of-care therapy for IPF and two other fibrotic lung diseases, and Contiva (avatrombopag) for thrombocytopenia associated with chronic liver disease. Its lead development candidate is Hydronidone, a derivative of pirfenidone, which the company is developing for CHB-associated liver fibrosis in the PRC and MASH-associated liver fibrosis in the United States. On March 2, 2026, the company agreed to a merger with Cullgen Inc., under which Cullgen would become a wholly owned subsidiary of Gyre, subject to Cullgen stockholder approval and an HSR Act filing. | Product or program | What it is | Stage | |---|---|---| | ETUARY (pirfenidone) | Anti-fibrotic therapy for idiopathic pulmonary fibrosis in the PRC | approved in the PRC | | Etorel (nintedanib) | Antifibrotic therapy for IPF and related fibrosing lung diseases in the PRC | approved in the PRC | | Contiva (avatrombopag) | Oral thrombopoietin receptor agonist for thrombocytopenia with chronic liver disease | approved in the PRC | | Hydronidone (F351) | Pirfenidone derivative for CHB-associated and MASH-associated liver fibrosis | | Summarised from the company's [10-K filed Mar 13, 2026](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/gyre-20251231.htm). ## Gyre Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$13.7 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | [$12.0 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | | Net income (loss) | [$9.9 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | [$17.9 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | | Cash from operations | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | [-$3.6 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | | Cash and equivalents | [$49.2 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526340448/) | [$11.8 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | | Short-term investments | [$15.4 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526340448/) | [$14.9 million](https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $43.3 million, plus short-term investments of $14.1 million, $57.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Gyre Therapeutics Has Gyre Therapeutics raised money recently? Our latest story on this, dated Nov 27, 2024: "Gyre Therapeutics sets up $50,000,000 at-the-market stock program with Jefferies". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gyre-therapeutics-sets-up-50-000-000-market-stock-program-jefferies/). Has Gyre Therapeutics sold convertible notes? Our latest story on this, dated Mar 2, 2026: "Gyre Therapeutics agrees to acquire Cullgen in all-stock deal valued at about $300 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gyre-therapeutics-agrees-acquire-cullgen-all-stock-deal-valued-about/). Is Gyre Therapeutics involved in a merger or acquisition? Our latest story on this, dated May 4, 2026: "Gyre Therapeutics completes all-stock acquisition of Cullgen valued at about $300 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gyre-therapeutics-completes-all-stock-acquisition-cullgen-valued-about/). What is the ticker symbol of Gyre Therapeutics? Gyre Therapeutics, Inc. trades under the ticker GYRE on NASDAQ. Where is Gyre Therapeutics listed? Gyre Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:L9S. What is the SEC CIK of Gyre Therapeutics? The SEC Central Index Key (CIK) for Gyre Therapeutics, Inc. is 1124105. Its filings are on SEC EDGAR. How many shares does Gyre Therapeutics have outstanding? 111,509,849 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Gyre Therapeutics listed under? Our directory records Gyre Therapeutics, Inc. under United States. What does Gyre Therapeutics do? Our directory classifies Gyre Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Gyre Therapeutics? The ISIN recorded for Gyre Therapeutics, Inc. is US4037831033. Does aibio.space cover Gyre Therapeutics? aibio.space lists Gyre Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Gyre Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Gyre Therapeutics develop? Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases. It operates in the PRC through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.), and has U.S. operations headquartered in San Diego, California. What is ETUARY (pirfenidone) from Gyre Therapeutics? ETUARY (pirfenidone): Anti-fibrotic therapy for idiopathic pulmonary fibrosis in the PRC Stage: approved in the PRC. What is Etorel (nintedanib) from Gyre Therapeutics? Etorel (nintedanib): Antifibrotic therapy for IPF and related fibrosing lung diseases in the PRC Stage: approved in the PRC. ## Investor discussion: Gyre Therapeutics Members talk about Gyre Therapeutics (GYRE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Gyre Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-04 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,3.03,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_ex99-1.htm) 2. 2026-03-02 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/ef20066398_ex99-1.htm) 3. 2025-05-22 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1124105/000114036125020208/ny20048719x1_424b5.htm) 4. 2024-11-27 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1124105/000114036124047979/ny20036484x5_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GYRE on TradingView](https://www.tradingview.com/symbols/NASDAQ-GYRE/). ## SEC filings and registration - **SEC name**: Gyre Therapeutics, Inc. - **CIK**: 1124105 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GYRE (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer
Smaller reporting company - **Business address**: 12730 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130 - **Phone**: (858) 284-0115 - **Shares outstanding**: 111,509,849 as of 2026-08-01 (10-Q filed 2026-08-07) - **Former names**: CATALYST BIOSCIENCES, INC.; TARGACEPT INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1124105/000114036126040506/ef20080299_8k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1124105/000114036126035189/ef20081441_8k.htm) filed 2026-09-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1124105/000114036126034401/ef20081104_8k.htm) filed 2026-08-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1124105/000119312526340448/gyre-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/gyre-20260807.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1124105/000114036126028716/ef20078088_8k.htm) filed 2026-07-16 - [S-3](https://www.sec.gov/Archives/edgar/data/1124105/000114036126025999/ny20070577x1_s3.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/ef20076059_8k.htm) filed 2026-06-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001124105), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Gyre Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GYRE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Gyre Therapeutics, Inc. - **Ticker**: GYRE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US4037831033 - **Other listed symbols**: GETTEX:L9S - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GYRE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/gyre-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Gyre Therapeutics (GYRE) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/gyre-therapeutics/